An international network for evaluating neuroprotective therapy after severe birth asphyxia.
Animal studies have shown great promise in their applicability to potentially neuroprotective therapies for severe birth asphyxia in human babies. It is now necessary to consider a strategy to evaluate some or all of these techniques within the context of human neonatal randomized control trials (RCT). We have set up a pilot study for an international RCT of mature babies with severe asphyxia (defined by an Apgar score of 5 or less at 10 minutes) and have shown that we can recruit from 120 centers in 17 countries an average of three babies a week, which is the required number to undertake a study over a 2-year period with sufficient power to show a significant improvement in outcome. Particular attention must be given in future studies to the size of improvement in outcome required, generalizability of entry criteria, and the appropriate measure of functional outcome in treated babies.
Department of Pediatrics, University of Leeds, United Kingdom.
M I
MI
Levene
D J
DJ
Evans
S
S
Mason
J
J
Brown
D000818:Animals; D001238:Asphyxia Neonatorum / Q000150:complications*; D006801:Humans; D007231:Infant, Newborn; D007391:International Cooperation; D008278:Magnesium Sulfate / Q000627:therapeutic use; D009422:Nervous System Diseases / Q000209:etiology / Q000517:prevention & control*; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic
D008278:Magnesium Sulfate